Ozempic Vision Loss: NAION, Semaglutide, and the Growing Lawsuit

NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy. It is a stroke of the optic nerve — the bundle of fibers that carries visual signals from the eye to the brain. When the small blood vessels supplying the front of the optic nerve are blocked or under-perfused, the nerve tissue is starved of oxygen and dies within hours.

The result is sudden, usually painless vision loss in one eye. Most people notice it on waking. Unlike a cataract or a refractive problem, NAION cannot be corrected with glasses or surgery. In roughly nine out of ten cases the vision that is lost never comes back, and about 15–25% of patients later develop NAION in the second eye.

In July 2024, researchers at Harvard's Mass Eye and Ear published a study in JAMA Ophthalmology reviewing more than 16,000 patient records. Patients prescribed semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — had a substantially higher rate of NAION than matched controls on other medications.

For patients taking semaglutide for type 2 diabetes, the study reported roughly a four-fold increase in NAION risk. For patients taking it for weight loss, the reported increase was roughly seven-fold. Follow-up analyses from other academic centers have reached similar directional findings, and European regulators asked Novo Nordisk in 2025 to add NAION to the Ozempic and Wegovy warning labels.

NAION comes on quickly — usually within a single day, often overnight. Because the damage is to the optic nerve rather than the eye itself, the eye typically looks normal from the outside.

NAION is the injury driving the current wave of claims, but it is not the only visual side effect patients are reporting. Some Ozempic and Wegovy users have described worsening diabetic retinopathy after starting the drug — an established, labeled risk tied to rapid improvement in blood sugar control. Others report new or worsened papilledema, optic disc swelling, and 'Ozempic eyes' changes to periorbital fat that alter appearance but not vision.

Only NAION is currently associated with the semaglutide product liability litigation. The other conditions may still matter to your treating physicians, but they typically do not form the basis of an injury claim on their own.

The federal Ozempic litigation — In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL 3094 — is consolidated before Judge Gene Pratter in the Eastern District of Pennsylvania. It initially focused on gastrointestinal injuries like gastroparesis, severe pancreatitis, and intestinal obstruction.

After the JAMA Ophthalmology study was published, plaintiffs' counsel began filing NAION claims into the same MDL. The court's Plaintiffs' Steering Committee treats NAION as a distinct injury track: separate short-form complaint category, separate expert witnesses, and its own bellwether discussions. Both new NAION-only plaintiffs and existing plaintiffs whose vision loss developed after filing have been able to add NAION to their pleadings.

Most firms working the NAION track look for a fairly specific set of facts. The stronger these are documented in your medical records, the stronger the claim.

NAION is a permanent injury. Case values in the NAION track generally reflect that: legally-blind-in-one-eye status, inability to drive at night or professionally, career impact for pilots, drivers, surgeons, and skilled tradespeople, and the ongoing risk of second-eye involvement.

As with the rest of MDL 3094, damages may include past and future medical costs, lost income and lost earning capacity, pain and suffering, and — if the internal Novo Nordisk documents obtained in discovery show the company knew of the NAION signal earlier than it warned — potentially punitive damages. No outcome is guaranteed, and every case is valued on its own facts.

Two things matter most in the first weeks: preserving evidence and protecting your legal deadline. Every state has a statute of limitations, and in most states the clock starts running from the date of diagnosis.